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Abstract
Neuroinflammation is strongly induced by cerebral ischemia. The early phase after the onset of ischemic stroke is
characterized by acute neuronal injury, microglial activation, and subsequent infiltration of blood-derived inflammatory
cells, including macrophages. Therefore, modulation of the microglial/macrophage responses has increasingly gained
interest as a potential therapeutic approach for the ischemic stroke. In our study, we investigated the effects of periph-
erally administered interleukin 13 (IL-13) in a mouse model of permanent middle cerebral artery occlusion (pMCAo).
Systemic administration of IL-13 immediately after the ischemic insult significantly reduced the lesion volume, allevi-
ated the infiltration of CD45+ leukocytes, and promoted the microglia/macrophage alternative activation within the
ischemic region, as determined by arginase 1 (Arg1) immunoreactivity at 3 days post-ischemia (dpi). Moreover, IL-13
enhanced the expression of M2a alternative activation markers Arg1 and Ym1 in the peri-ischemic (PI) area, as well as
increased plasma IL-6 and IL-10 levels at 3 dpi. Furthermore, IL-13 treatment ameliorated gait disturbances at day 7 and
14 and sensorimotor deficits at day 14 post-ischemia, as analyzed by the CatWalk gait analysis system and adhesive
removal test, respectively. Finally, IL-13 treatment decreased neuronal cell death in a coculture model of neuroinflam-
mation with RAW 264.7 macrophages. Taken together, delivery of IL-13 enhances microglial/macrophage anti-
inflammatory responses in vivo and in vitro, decreases ischemia-induced brain cell death, and improves sensory and
motor functions in the pMCAo mouse model of cerebral ischemia.
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Introduction
Despite intensive research during the last decades, ischemic
stroke remains a severely dementing and disabling disease
with limited options of effective therapy and stands among
the major causes of death worldwide. The interruption of ce-
rebral blood flow prompts a cessation of oxygen and nutrients
supply, resulting almost instantly in excitotoxicity, oxidative
stress, subsequent cellular damage, and apoptosis [1]. Upon
the ischemic injury, the primary neuroinflammatory response
is initiated by immune cells, such as rapidly activated resident
microglia and macrophages, resulting in the local production
of inflammatory cytokines and chemokines. In addition, sec-
ondary neuroinflammatory processes, widely initiated by po-
larized microglia and macrophages, astrocytes, and infiltrating
peripheral leukocytes, can further aggravate the injury in the
post-ischemic brain tissue [2]. During the early phase of
stroke, activated microglia and infiltrated blood-derived mac-
rophages secrete both pro- and anti-inflammatory factors, e.g.,
IL-1β, IL-6, tumor necrosis factor α (TNF-α), transforming
growth factor beta (TGF-β), and activate pro-inflammatory
enzymes, such as cyclooxygenase-2 (COX-2), and inducible
nitric oxide synthase (NOS2/iNOS) [2–4]. Conventionally,
macrophages and microglia are divided into the classical,
pro-inflammatory M1 phenotype and the beneficial, anti-
inflammatory M2 phenotype. Based on the distinct functions
of microglia/macrophages and their gene expression profiles,
M2 alternative activation state can be further classified into 4
subsets: M2a, M2b, M2c, and M2d [5]. M2a is typically in-
duced by IL-4 or IL-13 and results in upregulation of arginase
1 (Arg1), chitinase-like 3 (Chil3/Ym1), found in inflammato-
ry zone 1 (Fizz1), major histocompatibility complex II (MHC
II) molecules, transforming growth factor β (TGF-β), IL-1
receptor antagonist (IL-1RA), and enhanced expression of
scavenger receptors, e.g., mannose receptor (CD206) and
scavenger receptor-A (CD204) [6]. The M2a profile has been
associated with beneficial processes, such as neuroprotection,
extracellular matrix remodeling and tissue repair, and in-
creased phagocytic clearance of debris.
The patterns of microglia and macrophage activation vary
substantially between the infarct core and the peri-ischemic
(PI) zone. In the core area, microglia/macrophages acquire
an anti-inflammatory phenotype during the early phase after
stroke, but a large number of these cells undergoes apoptosis
and dies within the next days. In contrast, the pro-
inflammatory microglia and infiltrating macrophages are
abundant in the PI area in the acute phase after stroke [7, 8].
3 to 7 days post-ischemia (dpi), the anti-inflammatory
microglial cells are predominant in the inflamed brain to pro-
mote tissue repair before they are gradually replaced by pro-
inflammatory, M1-like polarized microglia/macrophages [7,
9, 10]. The number of M1-type microglia/macrophages in
the PI area peaks around 2 weeks following stroke [10].
Therefore, the idea to change the fate of microglia and mac-
rophages by shifting their activation state from M1 to M2 in
the penumbra during an early phase of ischemic response may
serve as a promising treatment strategy for ischemic stroke.
IL-13, an anti-inflammatory cytokine produced by Th2
cells, human naïve or memory CD4+ and CD8+ T cells, can
inhibit the secretion of pro-inflammatory mediators, including
nitric oxide (NO), IL-1β, IL-6, IL-12, and TNF-α [11], while
enhancing the expression of mannose receptor and MHC II
molecules [12]. In addition, IL-13 has been shown to suppress
the infiltration of inflammatory cells and axonal loss [13].
Because IL-13 can effectively trigger a shift from M1 to
M2a state [11, 14] and attenuate the production of inflamma-
tory mediators [11], we aimed to elucidate whether IL-13 is
able to reduce neuroinflammation and thus protect from
ischemia-induced brain damage. Based on the previous data
demonstrating IL-13’s beneficial, anti-inflammatory actions in
some models of neurological disorders [15–17], testing the
immunomodulatory potential of exogenous IL-13 administra-
tion was highly justified in the context of ischemic stroke. To
demonstrate the beneficial effects of IL-13 in the cerebral
ischemia, we employed a mouse model of permanent middle
cerebral artery occlusion (pMCAo) with subsequent adminis-
tration of murine recombinant IL-13. Intravenously adminis-
tered, IL-13 changed the activation state of microglia/
macrophages towards the M2a polarized, protective pheno-
type and provided functional recovery. Thus, our data show
that IL-13 is neuroprotective and serves as a candidate for the
treatment of ischemic stroke.
Materials and Methods
Animals
The National Animal Experiment Board of Finland approved
all animal experiments, which were in accordance with the
Council of Europe Legislation and Regulation for Animal
Protection. A total of 77, 4-month-old male BALB/cOlaHsd
mice (Envigo) were used in 4 independent experiments. The
mice were housed under a 12-h light/dark cycle, with access to
food and water ad libitum. All animals underwent a pMCAo
surgery. The animals were randomized and divided into 2
groups of either IL-13 or vehicle phosphate buffered saline
(PBS) treatment, using the GraphPad QuickCalcs software
(GraphPad Software, Inc. La Jolla, CA, USA). All tests and
data analyses were carried out blinded to the study groups.
Experimental Setup
Mice for 3 independent studies were treated intravenously
(i.v.) with 1 μg mouse recombinant IL-13 protein
(ThermoFisher Scientific, Waltham, MA, USA) or vehicle
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(PBS) for immunohistochemical analyses at 3 dpi (vehicle/IL-
13; N = 9), quantitative real-time PCR (qPCR) analyses at
3 dpi (vehicle/IL-13; N = 9), and behavioral testing (vehicle/
IL-13; N = 9). Another set of animals was either treated with
vehicle (N = 7), 2 μg (N = 8), or 5 μg (N = 8), to test the effi-
cacy of slightly higher doses (study overview in Table 1).
Altogether, 10 animals from vehicle-treated (N = 6) and IL-
13-treated (N = 4) groups were excluded from further analyses
due to bleeding during the surgery or otherwise inappropriate
middle cerebral artery (MCA) occlusion.
Ischemia Surgery and Treatment
All animals were initially anesthetized with 5% isoflurane and
the surgical anesthesia was maintained with 2% isoflurane in
70% N2O/30% O2. The body temperature was maintained at
37 ± 0.5 °C with a homeothermic control system connected to
a heating blanket and a rectal probe (Harvard apparatus;
PanLab, Cornella, Spain). The left MCA was permanently
occluded using a thermocoagulator (Aaron Medical
Industries Inc., Clearwater, FL, USA) as described previously
[18]. Briefly, a small skin incision was made between eye and
ear and the temporal bone was exposed. A small burr hole of
approximately 1 mm in diameter was drilled above the MCA
and the dura was removed. Following the removal of the dura,
the left MCA was lifted and cauterized, the muscle was
repositioned, and the skin wound was sutured. After recovery
from anesthesia, the animals received either PBS (in 100 μl
volume) or IL-13 (1, 2, or 5 μg/animal; volume 100 μl) i.v.
through the tail vein and were returned to normal cages. At 3
or 14 dpi, the mice were terminally anesthetized with
250 mg/kg of Avertin (Sigma-Aldrich, St. Louis, MO, USA)
and perfused transcardially with 80 ml ice-cold saline contain-
ing 2500 IU/l heparin (LEO 5000 IU/mL, Leo Pharma A/S,
Ballerup, Denmark).
Magnetic Resonance Imaging
Magnetic resonance imaging (MRI) was performed at 3 dpi to
image the brain infarct using a 9.4 TOxfordNMR 400magnet
(Oxford instrument PLC, Abington, UK). Multislice T2-
weighted images (repetition time 3000 ms, echo time 40 ms,
matrix size 128 × 256, and field of view 19.2 × 19.2 mm2,
slice thickness 0.8 mm and number of slices 12) were obtained
using a double spin-echo sequence with adiabatic refocusing
pulse. The images were then analyzed using an in-house-made
Aedes software under MATLAB environment (Math-works,
Natick, MA, USA). The lesion volume was quantified using
the formula: Infarct volume = (volume of right hemisphere −
(volume of left hemisphere − measured infarct volume)) / vol-
ume of right hemisphere. The lesion volume is expressed as
percentage [19].
Immunohistochemistry (IHC)
The animals were sacrificed at 3 dpi by transcardial perfusion
with ice-cold heparinized saline, and their brains were re-
moved and post-fixed in 4% paraformaldehyde for 18–20 h,
followed by cryopreservation in 30% sucrose for 48 h. The
brains were frozen in liquid nitrogen and cut into 20 μm cor-
onal sections using a cryostat (Leica Microsystems, Wetzlar,
Germany). 6 consecutive sections spanning through the le-
sion, each 400 μm apart, were taken for analysis from each
of the animals. Brain astrogliosis was visualized with glial
fibrillary acid protein (GFAP) staining, microglia/
macrophages were stained with ionized calcium-binding
adapter molecule 1 (Iba1), M2-type microglia/macrophages
were shown using arginase 1 (Arg1) staining, and leukocyte
infiltration was demonstrated by leukocyte common antigen
(CD45) staining. After blocking with 10% normal goat serum
(Merck Millipore, Billerica, MA, USA), the brain sections
were incubated with primary antibodies (GFAP, dilution
1:500, Dako, Glostrup, Denmark; Iba1, dilution 1:250,
Wako Chemicals, Tokyo, Japan; Arg1, dilution 1:200, Santa
Cruz Biotechnology, Dallas, TX, USA; CD45, dilution 1:100,
Bio-Rad, Hercules, CA, USA; active cleaved caspase-3, dilu-
tion 1:200, Cell Signaling, Danvers, MA, USA) overnight at
room temperature (RT). For Iba1 and Arg1 double staining,
prior to primary antibody incubation, sections underwent an-
tigen retrieval in aqueous 10 mM sodium citrate dihydrate
solution preheated to 92 °C, pH 6. Following overnight incu-
bation, the sections were washed with PBS containing 0.05%
Tween 20 (Sigma-Aldrich) and incubated for 2 h at RT with
secondary antibodies conjugated to Alexa Fluor 488 or 568
Table 1 The number of animals
for each experimental setup and
the number of animals excluded
due to an unsuccessful ischemia
induction
Total number of mice (N) IHC qPCR Behavioral testing Dosing scheme
Vehicle 34 9 9 9 7
IL-13 43
1 μg 27 9 9 9
2 μg 8 8
5 μg 8 8
Excluded vehicle 6 2 3 1 0
Excluded IL-13 4 1 2 1 0
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(dilution 1:200, ThermoFisher Scientific). Then slides were
embedded with Vectashield mounting medium containing
4′,6-diamidino-2-phenylindole (DAPI). Sections for CD45
and caspase-3 antibody staining were incubated with biotinyl-
ated secondary antibody (dilution 1:200) for 2 h and thereafter
with avidin-biotin complex reagent (all reagents from Vector
Laboratories, Burlingame, CA, USA). Nickel-enhanced 3,3′-
diaminobenzidine (DAB) was used for visualization of the
immunoreactivity. For all IHC staining, negative controls
were included in parallel sessions following the same proce-
dures, except for the incubation with primary antibodies. To
determine GFAP and Iba1 immunoreactivity, a region of in-
terest (ROI) of 718 × 532 μmwas imaged in the PI area at 10×
magnification using AX70 microscope (Olympus
Corporation, Tokyo, Japan) coupled to digital camera (Color
View 12 or F-View; Soft Imaging System, Munster,
Germany). For the Arg1 and cleaved caspase-3 staining, im-
ages of same size were taken from the ischemic core. For
CD45 staining, images of equal size were taken from the cor-
responding border zone area, where majority of the immuno-
reactivity was observed. All immunoreactivites were quanti-
fied using ImagePro Plus Software (Media Cybernetics, Silver
Spring, MD, USA). To quantify the immunoreactivity, a
predefined intensity range was chosen to minimize the back-
ground noise or artifacts. We then calculated the percentage of
immunoreactive areas. All analyses were done blinded to the
study groups. The confocal images for Iba1/Arg1
colocalization analysis were acquired from a precisely defined
PI area immediately adjacent to the ventral border of the is-
chemic lesion spanning across 3 consecutive sections (3, 4,
and 5, starting at the rostral part of the infarct) under 20×
magnification with Zeiss Axio Observer and Zeiss LSM 800
Airyscan module (Carl Zeiss AG, Jena, Germany). The repre-
sentative whole coronal slice images and magnified images of
immunoreactive areas from GFAP, Iba1/Arg1, and CD45
stainings were taken with 5× or 10×magnification, respective-
ly on Zeiss Axio Imager 2 coupled to Axiocam digital camera
(both Carl Zeiss AG) and using the Zen software. The repre-
sentative confocal microphotographs illustrating Iba1/Arg1
colocalization were taken under 40× magnification with
Zeiss Axio Observer and Zeiss LSM 800 Airyscan module
(Carl Zeiss AG).
Cytokine Secretion Analysis of Plasma
Buffered 129 mM sodium citrate was used as an antico-
agulant in the volume ratio 1:9 of anticoagulant to blood.
Collected blood samples were immediately centrifuged at
1500g for 15 min and plasma supernatants were addition-
ally spun down at 13000g for 2 min to remove any trace
of platelets. Plasma samples were aliquoted and stored at
− 70 °C until analysis. To assess the cytokine concentra-
tion in plasma, Cytometric Bead Array (CBA) Mouse
Inflammation Kit (BD Biosciences, San Jose, CA, USA)
was used according to the manufacturer’s guidelines. The
inflammation kit detects the following cytokines: IL-6,
IL-10, monocyte chemoattractant protein-1 (MCP-1),
IFN-γ, TNF, and IL-12p70. Data were acquired with
FACSCalibur (BD Biosciences) or CytoFLEX S
(Beckman Coulter, Indianapolis, IN, USA) and analyzed
by the FCAP Array v2 software (Soft Flow Hungary Ltd.,
Pécs, Hungary).
Quantitative Real-Time PCR Analyses of mRNA Levels
For quantification of gene expression, PI area, lesioned and
contralateral cortex approximately corresponding to PI area
were dissected at 3 dpi, snap-frozen in liquid nitrogen and
stored at − 70 °C until analysis. Total RNAwas isolated from
brain tissue homogenates and primary murine microglia cul-
tures with the mirVana miRNA Isolation Kit (ThermoFisher
Scientific). Reverse transcription was performed with 500 ng
of total RNA, Maxima reverse transcriptase, random hexamer
primers, and dNTPs in the presence of ribonuclease inhibitor
(all reagents ThermoFisher). The final cDNA concentration
used for the gene expression analyses was 2.5 ng/μl. The
relative expression levels of mRNAs encoding the selected
genes were analyzed in duplicates and measured according
to the manufacturer protocols by qPCR (StepOnePlus Real-
Time PCR System, ThermoFisher Scientific) using the fol-
lowing specif ic TaqMan gene expression assays
(ThermoFisher Scientific): Arg1 (Mm00479588_m1), Ym1
(Mm00657889_mH), Retnla (Mm00445109_m1), Il1b
(Mm00434228_m1), Il6 (Mm00446190_m1), Il10
(Mm00439614_m1), Mertk (Mm00434920_m1), Lgals3
(Mm0080290_m1), Tnfa (Mm00443258_m1), Il18
(Mm00434225_m1), Ptgs2 (Mm00478374_m1), Ifng
(Mm01168134_m1), andMarco (Mm00440265_m1). The re-
sults were normalized to the levels of endogenous control,
eukaryotic 18S rRNA (ThermoFisher Scientific). Relative
mRNA expression was calculated with the comparative
2−ΔΔCt method, in which Ct is the threshold cycle number
and results presented as fold changes in relation to the control
conditions.
Post-Surgery Assessment of the Locomotor Activity
Adhesive Removal Test To assess general forepaw and mouth
sensitivity (time-to-contact) and motor deficits (time-to-re-
move), we performed the adhesive removal test at 7 and
14 dpi as described previously [20]. 3 days prior to ischemia,
mice were placed for 60 s in a 60 × 80-cm opaque plastic box
for habituation. Next, a round adhesive sticker with 6.5 mm in
diameter (Bel-Art Products, Wayne, NJ, USA) was placed on
the hairless mid-paw area of each forelimb of the animal by
applying equal pressure. The mouse was placed back into the
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opaque box and time was recorded. During one trial, the an-
imal had 120 s time limit to remove the stickers. First sensing
of the adhesive and the removal time were logged. After a
short break, the animal was placed for a 30 s habituation into
the box and adhesive tapes were placed on the forepaws in
alternating fashion to the previous session. 3 trials per day and
mouse were performed. Each mouse was trained once before
baseline (BL) values were recorded. For the detection of pos-
sible somatosensory and motor deficits post-stroke, the medi-
an of time differences of sensing-to-removal between contra-
and ipsilateral forepaws were calculated.
CatWalk Gait Analysis The CatWalk automated gait analysis
system (Noldus Information Technology, Wageningen,
Netherlands) was used to assess gait and locomotor parame-
ters post-ischemia. Mice were tested in a dimmed room (<
20 lx of illumination). For the assessment, an enclosed
glass walkway (9 × 60 cm) was illuminated with a green,
internally reflected light. 40 cm below the walkway, a
high-speed camera captured the green light, reflected by
the paws upon glass contact, and transformed it into a
digital image [21]. The intensity threshold was set to
0.11, the camera gain was set to 18, and the maximum
allowed speed variation was set to 50%. The mice walked
spontaneously at their own speed and only uninterrupted
runs were saved for analysis. The animals were trained
twice before the BL recording on the day before
pMCAo surgery. All mice underwent CatWalk testing at
7 and 14 dpi.
Primary Microglia Cultures
Primary microglial cultures were prepared from C57BL/6J
neonatal mice of 0–3 postnatal day as described elsewhere
[22]. Briefly, mice were sacrificed by decapitation and
their brains dissected. After that, tissue was mechanically
dissociated and incubated in DMEM/F-12 supplemented
with 1% penicillin/streptomycin and 0.05% Trypsin-
EDTA (all ThermoFisher Scientific). Trypsin was
inactivated with complete media DMEM/F-12 containing
10% heat-inactivated fetal bovine serum (iFBS), 1%
penicillin/streptomycin (all ThermoFisher Scientific), the
tissue homogenized, seeded on 15 cm dishes and left at
37 °C, 5% CO2 for 3 weeks. Thereafter, the astrocyte
layer from mixed glial culture was trypsinized and the
remaining microglia collected and plated on 48-well or
6-well plate format at the density of 125 × 103 cells/well
and 1 × 106 cells/well, respectively. Microglia were treat-
ed with 20 ng/ml IFN-γ (Sigma-Aldrich) for 24 h follow-
ed by 10 ng/ml lipopolysaccharide (LPS, #L2630, sero-
type O111:B4, Sigma-Aldrich) for another 24 h (IFN-γ/
LPS treatment referred as M1), in combination with or
without 20 ng/ml IL-13 (ThermoFisher Scientific).
MTT Viability and LDH Release Assays
The MTT reduction assay was performed 24 h after exposure
to LPS as described earlier [23], with the following modifica-
tions. Briefly, following removal of the media, thiazolyl blue
tetrazolium bromide (MTT, Sigma-Aldrich) was added to
cells at a concentration of 1.2 mM, after which the cells were
incubated for 3 h at 37 °C and 5% CO2, until visible purple
crystals were formed. Thereafter, media were removed,
cells were lysed, and formazan crystals were dissolved
with DMSO (Fisher Scientific, Loughborough, UK).
Absorbances were read at 585 nm with a Wallac Victor2
1420 microplate reader (Perkin Elmer, Waltham, MA,
USA). The results were calculated as a percentage of rel-
ative MTT reduction compared to the control wells. The
Pierce LDH Cytotoxicity Assay Kit was used according to
the manufacturer’s instructions (ThermoFisher Scientific).
Briefly, assay reaction mixture was added to media sam-
ples collected 24 h after LPS exposure. After 30 min in-
cubation in the dark, stop solution was added to each
sample and the absorbances were measured at 490 nm.
The results are presented as percentage of LDH release
in relation to LDH positive control.
Flow Cytometry Analysis of N2a Cell Death
in Coculture with RAW 264.7 Murine Macrophages
For coculture experiments, mouse neuroblastoma Neuro-
2a (N2a) cells were seeded together with RAW 264.7
macrophages at a ratio of 1:1 and a density of 200 ×
103 cells/well on 12-well plate format, in DMEM supple-
mented with 10% iFBS and 1% P/S (all reagents
ThermoFisher Scientific). 24 h after plating, cocultures
were treated for 24 h with vehicle (PBS) or 25 ng/ml
LPS (serotype O111:B4, Sigma-Aldrich) in combination
with or without 20 ng/ml IL-13 (ThermoFisher Scientific).
Next, the cocultures were exposed for another 24 h to
vehicle or 100 ng/ml LPS and 25 ng/ml IFN-γ (Sigma-
Aldrich) in combination with or without 20 ng/ml IL-13.
Thereafter, the cells were collected and spun down and
the media were saved for NO release measurements.
Cells were incubated with CD11b-Alexa Fluor 647 anti-
body diluted 1:200 (BD Biosciences) for 30 min in the
dark at 4 °C, then washed with HBSS containing 3%
iFBS (ThermoFisher Scientific), resuspended in HBSS
with 3% iFBS, and counterstained with propidium iodide
at 2.5 μg/ml concentration (Sigma-Aldrich). To assess the
percentage of dead N2a cells, the Alexa Fluor 647 and
propidium iodide double staining was analyzed with
CytoFLEX S (Beckman Coulter). The dead N2a cells
were detected as Alexa Fluor 647 (CD11b) negative and
propidium iodide positive (UL quadrant).
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Nitric Oxide Release Measurements
NO production was indirectly assessed as described previous-
ly [24] by detection of nitrites in media samples obtained from
N2a and RAW 264.7 cocultures. A standard curve was pre-
pared using 0–100 μM sodium nitrite (Sigma-Aldrich) in cell
culture media. All samples in triplicates were transferred in
50 μl volume to a 96-well plate and 50 μl of Griess reagent
was added per well. The absorbance was then measured with
microplate reader Victor 2.0 (Perkin Elmer) at 544 nm and the
nitrite concentration was calculated.
Statistical Analyses
The statistical analyses were run with GraphPad Prism 5.03
(GraphPad Software, San Diego, CA, USA) using unpaired
two-tailed t test or one-way ANOVA followed by the
Bonferroni post hoc test to compare means of interest assum-
ing homoscedasticity and normality of variables. Based on
predetermined exclusion criteria, animals bleeding during
the surgery or with otherwise inappropriate MCA occlusion
were excluded from the study. Statistically significant outliers
as calculated by Grubb’s test using the GraphPad Prism soft-
ware were excluded from the datasets. Data are reported as
mean ± SEM unless otherwise stated, the statistical test used
and N numbers are stated in each figure legend. P values <
0.05 were considered statistically significant.
Results
IL-13 Treatment Significantly Decreased the Ischemic
Lesion Volume
To elucidate the neuroprotective role of IL-13 in ischemic
stroke, mice received either 100 μl of PBS as vehicle or IL-
13 at a dose of 1, 2, or 5 μg per animal right after cerebral
ischemia induction. Based on MRI of the mouse brains at
3 dpi, we were able to determine the infarct size. Analysis of
the infarct volumes revealed a significant reduction of the
infarct volume at all tested IL-13 doses when compared to
vehicle-treated mice, with 1 μg IL-13 dose decreasing the
ischemic lesion size most significantly (Fig. 1a, p = 0.0091;
Fig. 1b, p = 0.0327 and p = 0.0314).
IL-13 Treatment Significantly Reduced Leukocyte
Infiltration Without Altering Peri-ischemic
Astrogliosis
Analysis of GFAP immunoreactivity revealed that ischemic
stroke upregulated the astrocyte activation significantly. This
was seen in the PI area on the ipsilateral side of both treatment
groups when compared to contralateral side (data not shown).
However, IL-13 treatment failed to significantly alter the as-
trocytic activation and had only minor influence towards a
decrease of GFAP expression (Fig. 2a, p = 0.2618).
Infiltrating leukocytes expressing high levels of CD45 are
one of the hallmarks of inflammatory processes in the injured
brain. Although highly expressed by monocytes/macro-
phages, CD45 is present to a lower extent in resting microglial
cells [25]. In our analyses, a single injection of 1 μg IL-13
reduced significantly the number of CD45+ leukocytes infil-
trated into the ischemic core at 3 days post-injury (Fig. 2f, p =
0.0461).
IL-13 Treatment Increased the Type 2 Immune
Responses of Microglia/Macrophages
Within the Ischemic Brain
Microglia, the main resident immune cells in the brain, can
acquire a pro-inflammatory phenotype (M1), but under spe-
cific conditions, including stimulation with IL-13, they have
the ability to shift towards the alternative polarized phenotype
(M2a). With Iba1 IHC staining we evaluated brain microglia/
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Fig. 1 IL-13 treatment is protective against ischemia-induced cell loss.
Infarct volumes were quantified from MRI images obtained at 3 dpi for
vehicle-treated animals and animals treated with 1 μg of IL-13 (a). Lesion
volumes were quantified from MRI images obtained at 3 days post-
ischemia for vehicle-treated animals and animals treated with 2 or 5 μg
of IL-13 (b). Representative MRI images of the infarcted brain in vehicle
(c) and animals treated with 1 μg of IL-13 (d). Unpaired two-tailed t test
(a) and one-way ANOVA followed by the Bonferroni post hoc test (b).
Data are expressed as mean ± SEM. *p < 0.05, **p ˂ 0.01. VEH N = 7,
IL-13 N = 8
macrophages overall activation upon ischemic stroke.
Although the Iba1 immunoreactivity was evidently increased
after ischemic insult, we found no differences in Iba1 immu-
noreactivity between the vehicle and IL-13-treated mice at
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Fig. 2 IL-13 administration did not induce any significant changes in
astrogliosis, yet it significantly reduced the infiltration of CD45+
leukocytes in the ischemic brain parenchyma. Even though there was a
trend towards reduced astrocytic activation, IL-13 did not alter GFAP
expression significantly at 3 dpi (a). Representative images of entire cor-
onal sections from vehicle-treated (b) and IL-13-treated (c) animals.
Panels (d) and (e) represent GFAP immunoreactivity in the PI area of
vehicle- and IL-13-treated mice, respectively. Scale bar 100 μm. IL-13
markedly alleviated CD45+ leukocytes infiltrating the ischemic lesion site
(f). Representative images of entire coronal sections from vehicle-treated
(g) and IL-13-treated (h) animals. Panel (i) shows a ROI in a representa-
tive brain slice of a vehicle-treated mouse, whereas (j) displays a corre-
sponding ROI of an IL-13-treated mouse. Scale bar 200 μm. Unpaired
two-tailed t tests. Data are expressed as mean ± SEM. *p ˂ 0.05. VEH
N = 7, IL-13 N = 8
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3 dpi in the PI area (Fig. 3a, p = 0.5606). Using Arg1 IHC
staining, we investigated whether the protective effect of IL-
13 administration, observed in the PI and infarct area, is asso-
ciated with a phenotypic shift of microglia/macrophages from
M1 towards M2a. As shown in Fig. 3f–h, IL-13 treatment
promoted a major increase of M2a phenotype, resembling
microglia/macrophages following ischemic stroke in the
ipsilateral hemisphere when compared to vehicle treatment
(p = 0.0381). We also evaluated the colocalization percentage
of Iba1+/Arg1+ cells in the PI area of the mouse brains and did
not detect any differences between vehicle and IL-13-treated
animals (Fig. 3i, l–s, p = 0.7203). The number of Iba1+ and
Arg1+ cells specifically in the PI was also unchanged (data not
shown). IL-13 treatment did not alter the immunoreactivity of
cleaved caspase-3 in the PI area, indicating that this cytokine
at 3 dpi is neither exerting its beneficial effect by preventing
apoptosis nor further increasing the cell death in the ischemic
region (data not shown).
IL-13 Treatment Augmented the Expression of M2
Markers in the Ischemic Brain and Increased
the Anti-inflammatory Cytokine Levels in the Plasma
qPCR analysis of the PI area in the stroke brains at 3 dpi
revealed a significant increase of major alternative activation
markers Arg1 (Fig. 4a, p = 0.0408) and Ym1 (Fig. 4b, p =
0.0122), but not Fizz1/Rentla (data not shown) upon IL-13
treatment. IL-6 can act both as a pro-inflammatory and anti-
inflammatory cytokine depending on its involvement with
specific signaling pathways. It has been previously shown
that classic IL-6 signaling via transmembrane IL-6R drives
Fig. 3 IL-13 did not change the expression of Iba1 in the peri-ischemic
area, but induced Arg1 levels at 3 days post-stroke in the brains of mice
subjected to permanent ischemia. IL-13 did not influence Iba1 expression
in the PI area of the stroke brains (a). Representative images of entire
coronal sections from vehicle-treated (b) and IL-13-treated (c) animals.
Panels (d) and (e) represent the Iba1 immunoreactivity in the PI areas of
vehicle- and IL-13-treated mice, respectively. Quantitative analysis re-
vealed that IL-13 treatment significantly upregulated Arg1+ anti-
inflammatory microglia/macrophages (f). The microphotographs repre-
sent the Arg1 immunoreactivity in the lesion areas of vehicle-treated (g)
and IL-13-treated animals (h). IL-13 did not change the colocalization
percentage of Iba1+ and Arg1+ microglia/macrophages in the PI area (i).
Panels (j) and (k) depict Iba1+/Arg1+ colocalizing cells within the PI area
adjacent to ischemic core of vehicle- and IL-13-treatedmice, respectively.
Scale bar 200 μm. Panels (l–s) consist of confocal microphotographs of
the PI area from Iba1/Arg1 double stained brains of vehicle-treated (l–o)
and IL-13-treated (p–s) stroke animals. Scale bar 40 μm. Unpaired two-
tailed t tests. Data are expressed as mean ± SEM. *p ˂ 0.05. VEH N = 7,
IL-13 N = 8
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Fig. 4 IL-13 administration in vivo induced the expression levels of
myeloid alternative polarization markers both in the brain and in the
periphery at 3 days post-stroke. qPCR analysis of the PI area of the
ischemic brains of IL-13-treated mice revealed a marked increase of
Arg1 (a), Ym1 (b), and IL-6 (c) transcripts. IL-13 did not have any
significant effect on IL-10 (d), Mertk (e), and Lgals3 (f) expression levels
in the PI brains of these mice. As evaluated by CBA, IL-6 (g) and IL-10
(h) cytokines were significantly elevated in the plasma by a single IL-13
injection post-stroke. Unpaired two-tailed t tests. Data are expressed as
mean ± SEM. *p ˂ 0.05, **p ˂ 0.01. VEH N = 7–9, IL-13 N = 8
anti-inflammatory or regenerative processes [26]. As com-
pared to the vehicle-treated stroke animals, IL-6 expression
levels were markedly upregulated in the PI samples from the
animals treated with IL-13 (Fig. 4c, p = 0.0055). IL-10 ex-
pression in the PI area of ischemic brains was not
significantly affected by IL-13 administration (Fig. 4d, p =
0.1477). Phagocytosis-associated Mer receptor tyrosine ki-
nase (Mertk) expression levels in PI were unaltered between
IL-13 and vehicle animals (Fig. 4e, p = 0.0757); however, the
upregulation of galectin-3 (Lgals3/ Gal3) transcript levels
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nearly reached significance in IL-13-treated mice (Fig. 4f,
p = 0.0594). Gal3 deficiency has been reported to increase
the neuronal apoptosis and lesion volume in ischemic stroke
by impairing the microglial responses to the injury [4, 27]. In
addition, we also checked whether IL-13 reduces gene ex-
pression levels of the major pro-inflammatory molecules in-
cluding TNF-α, IFN-γ, Ptgs2/COX-2, IL-18, and macro-
phage receptor with collagenous structure (MARCO).
However, we did not observe significant changes in expres-
sion of these molecules (data not shown). CBA analysis at
3 dpi showed that IL-13-treated mice had significantly up-
regulated IL-6 and IL-10 protein levels in their plasma (Fig.
4g, p = 0.0448 and 4 h, p = 0.0341). In contrast, the protein
levels of pro-inflammatory cytokines including MCP-1,
TNF-α, IFN-γ, and IL-12 were unaltered between IL-13-
and vehicle-treated mice (data not shown).
The Sensitivity of the Contralateral Forelimb Was
Ameliorated After IL-13 Treatment in the Adhesive
Removal Test
The adhesive removal test was used to detect mouth and
forepaw sensitivity and possible somatosensory deficits
on the contralateral side, as well as motor performance
of both mouth and forelimbs. Our results showed that
IL-13 treatment significantly decreased the time needed
to remove the adhesive from the contralateral front paw
in the late stage after ischemic stroke, at 14 dpi (Fig. 5a,
p = 0.0345). Furthermore, at the same time point post-
stroke, there was a decrease in delay of removing the
adhesive between contra- and ipsilateral side following
IL-13 treatment, and this difference nearly reached statis-
tical significance (Fig. 5b, p = 0.0517).
Gait Analyses Revealed IL-13-Induced Improvements
7 and 14 Days After Ischemic Stroke
CatWalk automated gait analysis system was used to detect
possible IL-13-induced motor improvements post-stroke.
Both at 7 and 14 dpi, diagonal support, which is used the most
in healthy conditions and accounts for 60–70% of the support
types [28], was significantly ameliorated in the IL-13-treated
group (Fig. 5c, p = 0.0015 and p = 0.0094, respectively).
Some of the gait parameters of IL-13 animals were exclusive-
ly improved at 7 dpi. Support three, a parameter describing the
number of paws used to support body weight during a step
cycle, was reduced in the IL-13-treated group (Fig. 5d, p =
0.0349), as well as overall duty cycle (Fig. 5e, p = 0.0195),
defined as Stand expressed as a percentage of step cycle [29].
Furthermore, initial dual stance of the right front (RF) paw
(Fig. 5f, p = 0.0465), terminal dual stance of the left front
(LF) paw (Fig. 5g, p = 0.0253), and stand of the left hind
(LH) paw (Fig. 5h, p = 0.0242) were markedly shortened in
IL-13-treated mice. Kinetic parameter swing speed of the right
hind (RH) paw, meaning the velocity when paw is not in
contact with the glass plate, was notably higher in the group
of animals treated with IL-13 (Fig. 5i, p = 0.0336). 14 days
after ischemic insult support girdle, an interlimb coordination
parameter expressing the relative duration of contact with the
glass plate of 2 paws simultaneously (Fig. 5j, p = 0.0129), as
well as terminal dual stance of the ipsilateral hind paw (Fig.
5k, p = 0.0086) were reduced by IL-13 administration. Finally,
at 14 dpi, the stride length of the ipsilateral front paw, defining
the distance between successive placements of a paw, was
significantly increased in the IL-13 group (Fig. 5l, p =
0.0125).
IL-13 Treatment In Vitro Promoted the Alternative
Activation of Primary Microglia Concomitantly
Exposed to Pro-inflammatory Conditions
We first looked at the microglial viability under pro-
inflammatory conditions and assessed the potential cyto-
toxicity of IFN-γ/LPS (M1)/IL-13 treatment. The
microglial metabolic capacity of MTT reduction remained
unaltered when compared between M1 and M1/IL-13 ex-
posure (Fig. 6a, p = 0.0871), and the amount of released
LDH was unchanged among the treatment types (Fig. 6b,
p = 0.3374), indicating that IL-13 had no impact on cell
viability under inflammation and was not toxic to the
activated microglia.
qPCR analysis of the murine primary microglial cultures
exposed to a combination of M1 and IL-13 revealed a sub-
stantial increase ofM2-type marker Arg1 (Fig. 6c, p = 0.0001)
and strong downregulation of pro-inflammatory IL-1β tran-
script levels (Fig. 6e, p < 0.0001), compared to M1 treatment
alone. Ym1, considered as another marker of M2 activation,
Fig. 5 Behavioral improvement was observed after IL-13 treatment in
the adhesive removal test and CatWalk gait analyses at subacute and late
stages following ischemic stroke. The time of the adhesive tape re-
moval from the contralateral forepaw was significantly reduced after
IL-13 treatment when compared to untreated mice at 14 days post-
ischemia (a). At the same time point after ischemic stroke, the IL-
13-treated mice had shorter delay of removing the adhesive between
contra- and ipsilateral side (b). In the CatWalk analyses, both at 7
and 14 dpi IL-13-treated mice displayed improved diagonal support
(c). At 7 dpi, IL-13-treated mice showed decreased locomotor im-
pairments as indicated by decreased values of support three (d) duty
cycle of the left hind paw (e), initial dual stance of the right front
paw (f), terminal dual stance of the left front paw (g), and the left
hind paw’s stand parameters (h). Swing speed of the right hind paw
(i) was substantially increased comparing to the control, vehicle-
treated stroke group at 7 dpi. 14 days after ischemic insult, the mice
from IL-13 group demonstrated markedly reduced support girdle (j)
and terminal dual stance of the left hind limb (k), whereas their
stride length of the left front paw was increased in comparison to
the control group (l). Unpaired two-tailed t tests (a, b, d–l) and one-
way ANOVA followed by the Bonferroni post hoc test (c). Data are
expressed as mean ± SEM. *p ˂ 0.05, **p ˂ 0.01. VEH N = 8, IL-
13 N = 8
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was significantly upregulated upon IFN-γ/LPS stimulation
even without IL-13 treatment (Fig. 6d, p = 0.0001). IL-13 giv-
en together with M1 exposure upregulated MerTK (Fig. 6f,
p < 0.0001) and Lgals3 (Fig. 6g, p = 0.0255) expression, mol-
ecules shown to interact and participate in microglial phago-
cytosis [30, 31].
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Fig. 6 IL-13 promotes the shift of primarymicroglia polarization towards
M2 phenotype. The primary microglia viability measured by their
metabolic capacity of MTT reduction (a) and treatment cytotoxicity
assessed by LDH release (b) remained unaltered between M1 and M1 +
IL-13-treated cells. Concomitant IL-13 treatment with IFN-γ/LPS expo-
sure (M1 + IL-13) caused a robust increase of Arg1 expression in the
primary microglial culture as compared to M1 treatment alone (c).
Although the same treatment paradigm caused a significant decrease of
Ym1 transcript levels as compared to M1 exposure alone, Ym1 levels in
M1 + IL-13 group remained upregulated in comparison to the vehicle-
treated microglia (d). IL-13 exposure concomitant withM1 challenge was
able to alleviate the pro-inflammatory IL-1β expression as compared to
M1microglia (e). The levels of phagocytosis-relatedMertk (f) and Lgals3
(g) in M1 + IL-13 microglial cells were notably increased. Cytotoxicity
assays were repeated 3 times. One-way ANOVA followed by Bonferroni
post hoc tests. Data are expressed as mean ± SEM. *p ˂ 0.05, **p ˂ 0.01,
***p ˂ 0.001 versus vehicle-treated cells and ###p < 0.001 as compared to
M1-treated cells. VEH N = 5–6, M1 N = 6, M1 + IL-13 N = 5–6
IL-13 Exposure In Vitro Protected Neuronal N2a Cells
from Inflammation-Induced Death in Coculture
with RAW 264.7 Macrophages
To investigate the neuroprotective properties of IL-13 in
an in vitro coculture model of N2a and RAW 264.7 mac-
rophages, cocultures were exposed to vehicle, LPS, and
IFN-γ (M1) and M1 combined with IL-13 (Fig. 7a–d).
48 h of M1 stimulation induced the N2a cell death by
about 26% in comparison to vehicle-treated cells
(p < 0.0001), whereas IL-13 treatment combined with
M1 potently decreased the percentage of dead N2a cells
compared to M1 treatment alone (p < 0.0001). Moreover,
NO release in N2a and RAW 264.7 cocultures challenged
with pro-inflammatory stimulation was significantly alle-
viated by IL-13 treatment (Fig. 7e, p < 0.0001).
Discussion
Controlling neuroinflammation, especially the processes of
inflammation-induced secondary brain damage, is crucial to
improve the ischemic stroke outcome. Here, for the first time,
we demonstrate that i.v. administration of exogenous recom-
binant murine IL-13 is beneficial in a mouse model of
pMCAo. A single peripheral injection of IL-13 markedly re-
duced the ischemic brain damage, elicited anti-inflammatory
responses in the injured brain, and provided long-term func-
tional improvement by ameliorating sensorimotor deficits. IL-
13 has been demonstrated to mediate a phenotypic shift from
pro-inflammatory M1-type microglia/macrophages towards
the anti-inflammatory M2-phenotype in a number of studies
[14–16, 32–34]. Importantly, mesenchymal stem cell (MSC)-
based IL-13 delivery orchestrated alternative polarization of
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Fig. 7 IL-13 decreases N2a neuroinflammation-induced cell death in a
coculture model with RAW 264.7 macrophages. In comparison to
vehicle-treated cells (a), the proportion of CD11b negative, propidium
iodide positive (PI+), and dead N2a cells was increased by about 26%
in LPS and IFN-γ exposed cocultures (b). IL-13 treatment combined with
LPS and IFN-γ markedly decreased the percentage of PI+ N2a cells as
compared to LPS and IFN-γ challenge alone (c, d). NO production in
N2a and RAW 264.7 cocultures under pro-inflammatory conditions was
notably attenuated by IL-13 exposure (e). One-way ANOVA followed by
Bonferroni post hoc tests. Data are expressed as mean ± SEM.
***p ˂ 0.001 versus vehicle-treated cells and ###p < 0.001 as compared
to M1-treated cells. VEH N = 4, M1 N = 6, M1 + IL-13 N = 6
macrophages and resulted in improved functional recovery
following SCI [32]. Most recently, IL-13-overexpressing
MSCs were found to enhance the transmigration of alterna-
tively activated macrophages into the infarct area [17]. These
data support our finding that IL-13 promotes the phenotypic
shift of microglia/macrophages towards the anti-inflammatory
type M2a, hence providing the neuroprotection and long-term
functional recovery.
In this study, IL-13 treatment provided a significant
neuroprotection by reducing the ischemic infarct size
when administered right after the ischemic onset.
Irrespective of the doses we used in our study, we found
a consistent reduction in lesion volume. IL-13 treatment
did not significantly change the overall Iba1 immunoreac-
tivity of microglia/macrophages in the PI area at 3 dpi.
Instead, we detected an increased Arg1 immunoreactivity
within the infarct area in mice treated with IL-13, suggest-
ing the importance of alternatively activated infiltrating
macrophages in neuroprotection. In fact, cell-based deliv-
ery of IL-13 has been demonstrated to promote the alter-
native polarization of microglia and/or macrophages in
the mouse model of SCI and tMCAo [17, 32]. Although
we did not observe an increased percentage of the cells
immunoreactive for both Iba1+ and Arg1+ in the PI area
of the animals treated with IL-13, the Arg1 transcript
levels in this area were notably increased, which is in line
with the previous studies [34, 35]. In addition, our data
showed a decrease of CD45+ infiltrating leukocytes in the
infarcted brains of IL-13-treated mice. Thus, the protec-
tive effect of IL-13 in ischemic stroke could be partially
explained by the reduced infiltration of peripheral im-
mune cells and increased proportion of M2-skewed cells
in the ipsilateral hemisphere. Astrogliosis was not sub-
stantially affected by IL-13 treatment, as we observed
similar levels of GFAP immunoreactivity following ische-
mia in vehicle and IL-13-treated mice.
Peripheral inflammation is known to exacerbate the ische-
mic damage [18, 36]. As such, the modulation of peripheral
inflammation has been shown to provide neuroprotection in a
number of studies [35, 37–39]. Therefore, we analyzed wheth-
er IL-13 treatment modulates the peripheral immune response
after brain ischemia. Indeed, we observed increased levels of
the anti-inflammatory cytokine IL-10 in plasma. Although
subject to debate, there are studies indicating that low levels
of IL-10 in plasma correlate with neurological deterioration
[40], which would support our findings. IL-6 can be consid-
ered either a pro- or anti-inflammatory cytokine, depending on
its signaling pathway [26]. This cytokine was upregulated
both on the mRNA level in the PI area and on the protein level
in the plasma of IL-13-treated animals. The anti-inflammatory
role and thus the protective effect of IL-6 in ischemic stroke is
supported by a previous study, in which repetitive i.v. admin-
istration of IL-6 protein ameliorated the behavioral outcome
after pMCAo inmice [41]. However, IL-13 was unable to alter
the levels of major pro-inflammatory molecules like TNF-α
and IFN-γ in both CNS and periphery. This can be explained
partially by the fact that IL-13 does not inhibit the pro-
inflammatory mediators but rather induces the expression of
molecules associated with type 2 immune response [5].
Ischemic stroke is a highly debilitating disease and the
functional recovery is warranted by the therapeutic treatments.
IL-13 was able to ameliorate behavioral deficits at subacute
and chronic stages compared to control mice as evident in
CatWalk gait analyses and adhesive removal test. At 7 dpi,
IL-13-treated mice showed notable improvements in several
parameters associated with locomotor abilities as reported pre-
viously [29, 42]. The support diagonal, the type of limb sup-
port dominant in the healthy conditions [28], was improved at
both 7 and 14 dpi. At 14 dpi, IL-13-treated mice no longer
required to compensate abnormal movements of the contralat-
eral hind limb and showed improved coordination patterns
during the step cycle [29]. Finally, the adhesive removal test
displays yet another improvement of the stroke-induced sen-
sorimotor deficits in the IL-13-treated group.
In addition to modulation of the infiltrating peripheral
immune cells, IL-13 is expected to cross the damaged BBB
to some extent and thus act on CNS immune cells. In fact,
both IL-4 and IL-13 have been shown to mediate the alter-
native microglial activation in the brain [43]. Therefore, we
tested the effect of IL-13 in in vitro primary microglia
following M1-type (IFN-γ combined with LPS) stimula-
tion. As expected, microglial cells challenged with M1
stimulation responded with a robust upregulation of the
M1-like activation marker IL-1β [44]. IL-13 treatment
with simultaneous M1 stimulation alleviated IL-1β expres-
sion and concomitantly induced transcript levels of M2-
associated marker Arg1, which is in agreement with our
in vivo data. Intriguingly, Ym1 was significantly upregu-
lated with M1 stimulation alone. In fact, a previous study
has shown that LPS exposure increased the expression of
Ym1 in rat primary microglia 24 h after stimulation, sug-
gesting that Ym1 is not a typical M2 marker for these cells
[45]. In addition, combined IL-13 and M1 stimulation in-
creased MerTK and Gal3 levels, a receptor and its ligand
known to be associated with the phagocytic activity of
microglial cells [30, 31]. However, these results could not
be obtained from the brains of IL-13-treated mice subject-
ed to permanent ischemia, as the expression of MerTK
remained unaffected in the PI regions, and the moderate
increase in Gal3 levels failed to reach statistical signifi-
cance. Likewise, microglial viability under inflammation
was unaltered by IL-13, as evident by the results of MTT
reduction and LDH release assays in vitro and caspase-3
immunoreactivity analysis in in vivo studies, which is in
contrast to the previous findings reported by others [46,
47]. These discrepancies may be partially explained due
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to the differences in the models, IL-13 doses and the time
points used.
Our in vivo data suggested that IL-13-mediated neuropro-
tection in ischemic stroke might be exerted by alternatively
polarized peripheral immune cells infiltrating the ischemic
infarct site. Based on this observation, we employed an in vitro
neuroinflammation model using RAW 264.7 macrophages
cocultured with N2a cells. The percentage of propidium
iodide-positive (dead) N2a cells was markedly lower in cocul-
tures exposed to IFN-γ, LPS, and IL-13 compared to cocul-
tures challenged only with IFN-γ and LPS. NO is either di-
rectly neurotoxic or induces neuronal death through generated
peroxynitrite, which inhibits mitochondrial respiration and
elicits glutamate release resulting in excitotoxicity and neuro-
nal apoptosis [48]. In our model, NO released from the cocul-
tures was significantly attenuated by IL-13 under inflamma-
tory condition. This might be attributed to the increased ex-
pression of Arg1 by macrophages, which subsequently re-
duces the bioavailability of arginase, the substrate for iNOS.
Although we did not measure the concentration of cytokines
from coculture media, the possible reduction of pro-
inflammatory cytokine levels by IL-13 cannot be ruled out.
There is an increasing evidence that induction of Th2-type
immune response has neuroprotective effects following stroke
by limiting progression of the ischemic infarct [49–52].
However, repetitive administration of M2 cytokines after is-
chemic stroke can enhance the post-stroke immunosuppres-
sion, thereby facilitating bacterial infections and increasing
mortality [53, 54]. In our study, we used a single dose of IL-
13 in a pMCAo model that produces strictly cortical lesions.
Hence, we expected a minor immunosuppression. Whether
IL-13 treatment is efficient at a clinically relevant time point
in more severe models of ischemia where acute post-stroke
immunosuppression is observed remains unknown.
Our study reports for the first time in the animal model of
ischemic stroke the beneficial actions of i.v. administered anti-
inflammatory cytokine IL-13. Apart from decreasing the is-
chemic infarct size, the histological analyses revealed that a
single dose of IL-13 administered immediately post-stroke
markedly induced the proportion of M2-type microglia/
macrophages in the ischemic area of the brain and significant-
ly ameliorated the long-term sensorimotor deficits.
Importantly, our findings have potential implications in the
clinical practice and therefore IL-13 treatment can be consid-
ered a novel therapeutic approach for the treatment of cerebral
ischemia.
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